Theratechnologies Management
Management criteria checks 3/4
Theratechnologies' CEO is Paul Lévesque, appointed in Apr 2020, has a tenure of 4.67 years. total yearly compensation is $1.90M, comprised of 34.7% salary and 65.3% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth CA$182.00K. The average tenure of the management team and the board of directors is 6.5 years and 4.4 years respectively.
Key information
Paul Lévesque
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 34.7% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 6.5yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH)
May 03
Theratechnologies Inc.'s (TSE:TH) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Apr 10Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts
Feb 24Investors Don't See Light At End Of Theratechnologies Inc.'s (TSE:TH) Tunnel And Push Stock Down 27%
Feb 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2024 | n/a | n/a | -US$3m |
| May 31 2024 | n/a | n/a | -US$7m |
| Feb 29 2024 | n/a | n/a | -US$18m |
| Nov 30 2023 | US$2m | US$659k | -US$24m |
| Aug 31 2023 | n/a | n/a | -US$29m |
| May 31 2023 | n/a | n/a | -US$36m |
| Feb 28 2023 | n/a | n/a | -US$49m |
| Nov 30 2022 | US$2m | US$657k | -US$47m |
| Aug 31 2022 | n/a | n/a | -US$49m |
| May 31 2022 | n/a | n/a | -US$51m |
| Feb 28 2022 | n/a | n/a | -US$35m |
| Nov 30 2021 | US$2m | US$639k | -US$32m |
| Aug 31 2021 | n/a | n/a | -US$27m |
| May 31 2021 | n/a | n/a | -US$25m |
| Feb 28 2021 | n/a | n/a | -US$24m |
| Nov 30 2020 | US$2m | US$379k | -US$23m |
Compensation vs Market: Paul's total compensation ($USD1.90M) is above average for companies of similar size in the Canadian market ($USD164.16K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Lévesque (60 yo)
4.7yrs
Tenure
US$1,900,415
Compensation
Mr. Paul Lévesque has been President, Chief Executive Officer and Director at Theratechnologies Inc. since April 6, 2020. Mr. Lévesque boasts many years of experience in the pharmaceutical field. After beg...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.7yrs | US$1.90m | 0.16% CA$ 182.0k | |
| Senior VP & CFO | 8.8yrs | US$654.50k | 0.034% CA$ 39.4k | |
| General Counsel & Corporate Secretary | 17.7yrs | US$468.88k | 0.0098% CA$ 11.3k | |
| Senior VP & Chief Medical Officer | 8.4yrs | US$656.79k | 0.032% CA$ 37.1k | |
| Global Commercial Officer | 3.8yrs | US$604.30k | 0.11% CA$ 128.1k | |
| Vice President of Human Resources | 3.6yrs | no data | no data |
6.5yrs
Average Tenure
59.5yo
Average Age
Experienced Management: TH's management team is seasoned and experienced (6.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.7yrs | US$1.90m | 0.16% CA$ 182.0k | |
| Independent Chairman | 3.5yrs | US$65.48k | 0.13% CA$ 149.4k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.2yrs | US$64.00k | 0.30% CA$ 343.7k | |
| Independent Director | 11.7yrs | US$141.74k | 0.24% CA$ 277.2k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.6yrs | US$66.96k | 0.096% CA$ 110.4k | |
| Independent Director | 3.6yrs | US$61.31k | 0.030% CA$ 34.4k |
4.4yrs
Average Tenure
67.5yo
Average Age
Experienced Board: TH's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2023/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Theratechnologies Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zhang | BMO Capital Markets U.S. (Historical) |
| Douglas Loe | Byron Capital Markets |
| Dewey Steadman | Canaccord Genuity |